NASDAQ · CRDF
Cardiff Oncology, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CRDF: Nov 5, 2026
Cardiff Oncology, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.17.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.13 | $-0.15 | 4 |
| Dec 2026 | $-0.15 | $-0.12 | $-0.17 | 4 |
| Mar 2027 | $-0.13 | $-0.09 | $-0.16 | 3 |
| Jun 2027 | $-0.13 | $-0.08 | $-0.18 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · BNK Invest- RTTNews · Oct 28, 3:02 AM EDTCardiff Names Alland Interim Medical Chief Ahead Of Planned Phase 3 Cancer Trial(RTTNews) – Shares of Cardiff Oncology, Inc. (CRDF) fell 5.70% in after-hours trading on Tuesday after the clinical-stage biotechnology company announced Leila Alland's appointment as interim chief medical officer (CMO).
- Fintel · Oct 27, 10:08 PM EDTCardiff Oncology Appoints Leila Alland as Interim Chief Medical Officer and Increases Authorized Shares to 300,000,000Cardiff Oncology, Inc. announced that Dr. Roger Sidhu separated from the company as Chief Medical Officer on October 22, 2026, in connection with a mutually agreed upon transition. On October 23, 2026, the company entered into an amended and restated consulting agreement with Lei
- RTTNews · Oct 23, 6:32 AM EDTCardiff's Onvansertib Wins FDA Orphan Drug Designation For Rare Blood Cancer(RTTNews) – Cardiff Oncology, Inc. (CRDF) on Wednesday said the U.S. Food and Drug Administration granted orphan drug designation to Onvansertib for chronic myelomonocytic leukemia.
- Fintel · Oct 22, 9:18 PM EDTCardiff Oncology, Inc. Stockholders Approve Increase in Authorized Common Stock to 300,000,000On October 22, 2026, Cardiff Oncology, Inc. held its Special Meeting of Stockholders, where a total of 48,084,246 shares of common stock were represented in person or by valid proxies, constituting a quorum. At the meeting, stockholders approved an amendment to the company's Amen
- Fintel · Sep 15, 3:07 PM EDTHC Wainwright & Co. Upgrades Cardiff Oncology to Buy from NeutralFintel reports that on September 15, 2026, HC Wainwright & Co. upgraded their outlook for Cardiff Oncology (NASDAQCM:CRDF) from Neutral to Buy. This rating action follows a prior action on June 1, 2026, when the same firm downgraded the company from Buy to Neutral.Cardiff Onc
- RTTNews · Sep 15, 2:43 PM EDTBiotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers(RTTNews) – Several biotech stocks were in focus Tuesday, including PDS Biotech following a potential $22.55 million PIPE financing; Avaí Bio after completing testing of its GMP Master Cell Bank; Clene following a $4 million registered direct offering; NurExone after entering an
- RTTNews · Sep 15, 9:46 AM EDTCardiff Oncology Resolves Onvansertib Licensing Dispute With Nerviano; Shares Rise(RTTNews) – Cardiff Oncology, Inc. (CRDF) and Nerviano Medical Sciences S.r.l. announced that they have settled their licensing dispute over onvansertib, Cardiff's lead drug candidate, amended their 2017 agreement, and expanded their collaboration to support the drug's Phase 3 de
- RTTNews · Aug 12, 8:55 AM EDTCardiff Loss Narrows In Q2; Directs Resources To Phase 3 For Onvansertib In Q1 '27(RTTNews) – Cardiff Oncology, Inc. (CRDF) a clinical-stage oncology company, reported second quarter results, reflecting a narrower loss primarily driven by lower operating expenses. The company in particular noted reduced Research and Development (R&D) expenses following the com
- BNK Invest · Jul 17, 11:43 AM EDTFriday 7/17 Insider Buying Report: CRDF, FISAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. At Cardiff Oncology, a filing with the SEC revealed that on Tuesday, Gary W. Pace
- RTTNews · Jul 15, 9:05 AM EDTCardiff Oncology Prices $10 Mln Registered Direct Offering; Shares Fall 27% In Pre-Market(RTTNews) – Cardiff Oncology, Inc. (CRDF), a clinical-stage biotechnology company, on Wednesday announced entering into a definitive agreement for the purchase and sale of 8.57 million shares of its common stock and accompanying warrants in a registered direct offering at a price
- RTTNews · Jun 5, 10:26 AM EDTWeekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN(RTTNews) – This week, the biotech sector saw a wave of regulatory approvals in the U.S., alongside study halts, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical study data readouts spanned multiple therapeutic areas, inclu
- RTTNews · Jun 2, 11:53 AM EDTCardiff Presents Positive Phase 2 Data For Onvansertib In Colorectal Cancer, Highlights 72% ORR(RTTNews) – Cardiff Oncology Inc. (CRDF), a clinical-stage biotechnology company, on Tuesday announced positive Phase 2 results for Onvansertib in combination with standard-of-care regimens in treating first-line RAS-mutated metastatic colorectal cancer (mCRC). The data was prese
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cardiff Oncology, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.